# Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions

> **NCT05536037** · PHASE1 · TERMINATED · sponsor: **Thomas Jefferson University** · enrollment: 4 (actual)

## Conditions studied

- Erythroplakia
- Leukoplakia
- Oral Cavity Carcinoma
- Proliferative Verrucous Leukoplakia

## Interventions

- **DRUG:** Metformin
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT05536037
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-04
- **Primary completion:** 2024-03-16
- **Final completion:** 2024-03-16
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05536037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05536037, "Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05536037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*